More on Bristol-Myers (BMY) Q2: net profit -28% to $645M as patent expirations for Plavix,...


More on Bristol-Myers (BMY) Q2: net profit -28% to $645M as patent expirations for Plavix, Avapro and Avalide take their toll, although sales of other drugs rise. U.S. sales -27% to $2.6B, non-U.S. -1% to $1.9B. Cuts FY EPS guidance to $1.78-1.88 from $1.90-2 prior; keeps adjusted EPS forecast at $1.90-2 vs. consensus of $1.94.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs